Compare AbbVie Inc (ABBV) vs Electronic Arts Inc. (EA) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Electronic Arts (EA) trades at $205.44, up 0.11% on the day, with a bullish technical signal from moving averages and strong profitability metrics including a 78.97% gross margin. Recent news highlights a potential $55 billion acquisition by Saudi investors pending EU approval and the launch of new gaming titles and an advertising platform, indicating active business development.

The stock presents a mixed outlook with high valuation ratios (P/E of 58.46) posing a risk, but analyst consensus leans positive with no sell ratings. Key risks include earnings volatility, as seen in recent misses, and regulatory scrutiny over the acquisition. Upside potential hinges on successful game launches and the advertising initiative driving future growth.